Hemodynamic response to norepinephrine with and without inhibition of nitric oxide synthase in porcine endotoxemia.
The objective of this study was to determine the circuit and cardiac effects of norepinephrine (NE) with and without endotoxin, and how these responses are modified by the inhibition of nitric oxide synthase (NOS). We anesthetized eight pigs and instrumented them for measurements of cardiac output (Q), arterial pressure (Part), and mean pulmonary arterial pressure (Ppa). We also placed a 40-ml balloon in the right atrium for transient obstruction of flow and measurement of the mean circulatory filling pressure (MCFP) and resistance to venous return (RVR). After baseline measurements, animals were treated with 10 microg/kg/h of Escherichia coli endotoxin. At 105 min the measurements were repeated. We then infused 12.5 mg/kg of N(G)-nitro-L-arginine methyl ester (L-NAME) for 10 min and repeated the measurements. At baseline, at the end of endotoxin infusion, and after L-NAME infusion we infused 3, 9, and 27 microg/min of NE for 10 min each, and recorded hemodynamic measurements at each dose. NE shifted the venous return curve (i.e., increased MCFP) to the right without changing RVR, and increased cardiac output (CO) both at baseline and after endotoxin. Endotoxemia markedly flattened the dose-response curves for the change in Part, Ppa, CO, and heart rate with NE. The peak response of Part to NE after endotoxemia was restored with L-NAME, but the other dose-response curves were not affected. NE also did not shift the venous return curve after L-NAME. Furthermore, the increase in Part with NE was of shorter duration after L-NAME than in the baseline condition. In conclusion, NE shifts the venous return curve to the right and improves CO in endotoxic and nonendotoxic conditions. Endotoxemia decreases the arterial responsiveness to NE. L-NAME partly restored this loss of responsiveness in arteries but not in the venous circulation.
Datta
P
P
Departments of Medicine and Physiology, Critical Care Division, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
Magder
S
S
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D019446:Endotoxemia / Q000503:physiopathology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004927:Escherichia coli Infections / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D009638:Norepinephrine / Q000494:pharmacology*; D011652:Pulmonary Circulation / Q000187:drug effects; D013552:Swine; D014655:Vascular Resistance / Q000187:drug effects
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D004791:Enzyme Inhibitors; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine